Ilovetech, Speculating, but I believe monetizing the platform will be what the Franchise model does. Possibly the franchisees will be oncologists and BPs, who all want access to DCVax for their cancer patients. Doctors get support for off-label use. BPs get access to DCVax for combination therapies and clinical trials. And NWBO gets access to more cancer patients and cancer types, or rather gives cancer patients access to DCVax.
My opinion is a licensing structure for a large upfront payment and royalty, say 15%, is a less preferable way to monetize. That is equivalent to selling 85% of the business (future revenues). I prefer to keep 100% of the product sales, be a product company. That is the path towards being a Big Pharma. The reward will be a valuation multiple applied against a larger sales number.
Market Data 
Markets 
AI
